|
gptkbp:instanceOf
|
immunosuppressant
|
|
gptkbp:approvalYear
|
1995
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L04AA06
|
|
gptkbp:brand
|
gptkb:CellCept
gptkb:Myfortic
|
|
gptkbp:CASNumber
|
128794-94-5
|
|
gptkbp:chemicalFormula
|
C23H31NO7
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Roche
|
|
gptkbp:eliminationHalfLife
|
16-18 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mycophenolate mofetil
|
|
gptkbp:interactsWith
|
gptkb:acyclovir
live vaccines
antacids
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits inosine monophosphate dehydrogenase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
433.5 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:prodrugOf
|
gptkb:mycophenolic_acid
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gastrointestinal upset
leukopenia
teratogenicity
increased risk of infection
|
|
gptkbp:usedFor
|
prevention of organ transplant rejection
treatment of autoimmune diseases
|
|
gptkbp:bfsParent
|
gptkb:MMF
|
|
gptkbp:bfsLayer
|
7
|